

Ora Israel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/739202/publications.pdf>

Version: 2024-02-01

62
papers

4,494
citations

126907

33
h-index

144013

57
g-index

66
all docs

66
docs citations

66
times ranked

3936
citing authors

#	ARTICLE	IF	CITATIONS
1	EANM/SNMMI Guideline for ¹⁸ F-FDG Use in Inflammation and Infection. Journal of Nuclear Medicine, 2013, 54, 647-658.	5.0	496
2	Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. Journal of Nuclear Medicine, 2003, 44, 1200-9.	5.0	398
3	¹⁸ F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients. Journal of Nuclear Medicine, 2010, 51, 25-30.	5.0	352
4	A review on the clinical uses of SPECT/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1959-1985.	6.4	347
5	SPECT/CT in tumor imaging: Technical aspects and clinical applications. Seminars in Nuclear Medicine, 2003, 33, 205-218.	4.6	179
6	Prosthetic Vascular Graft Infection: The Role of 18F-FDG PET/CT. Journal of Nuclear Medicine, 2007, 48, 1230-1236.	5.0	177
7	SPECT/CT hybrid imaging with 111 In-pentetreotide in assessment of neuroendocrine tumours. Clinical Endocrinology, 2003, 59, 565-573.	2.4	167
8	PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. Journal of Nuclear Medicine, 2005, 46, 758-62.	5.0	156
9	Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1990-2012.	6.4	139
10	Technetium-99m-MIBI SPECT/CT in Primary Hyperparathyroidism. World Journal of Surgery, 2006, 30, 76-83.	1.6	129
11	Do Hyperglycemia and Diabetes Affect the Incidence of False-Negative ¹⁸ F-FDG PET/CT Studies in Patients Evaluated for Infection or Inflammation and Cancer? A Comparative Analysis. Journal of Nuclear Medicine, 2010, 51, 1015-1020.	5.0	125
12	Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer, 1988, 61, 2439-2443.	4.1	116
13	SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection. Journal of Nuclear Medicine, 2006, 47, 587-94.	5.0	114
14	The diabetic foot: initial experience with 18F-FDG PET/CT. Journal of Nuclear Medicine, 2005, 46, 444-9.	5.0	108
15	The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Seminars in Nuclear Medicine, 1995, 25, 60-71.	4.6	97
16	FDG avidity and PET/CT patterns in primary gastric lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1424-1430.	6.4	74
17	Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with 67Ga Scintigraphy. Radiology, 2000, 214, 253-257.	7.3	73
18	The fusion of anatomic and physiologic imaging in the management of patients with cancer. Seminars in Nuclear Medicine, 2001, 31, 191-205.	4.6	73

#	ARTICLE	IF	CITATIONS
19	Breast Cancer: Role of SPECT and PET in Imaging Bone Metastases. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 408-415.	4.6	72
20	Positron emission tomography in the evaluation of lymphoma. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 166-179.	4.6	69
21	Unexpected foci of 18F-FDG uptake in the breast detected by PET/CT: incidence and clinical significance. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1558-1564.	6.4	68
22	Hodgkin Disease: Prediction of Outcome with 67Ga Scintigraphy after One Cycle of Chemotherapy. <i>Radiology</i> , 1999, 210, 487-491.	7.3	64
23	FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1280-1284.	6.4	58
24	Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, S65-S81.	6.4	55
25	Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study. <i>Radiology</i> , 2003, 227, 353-360.	7.3	53
26	SPECT/CT: Standing on the Shoulders of Giants, It Is Time to Reach for the Sky!. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1284-1291.	5.0	50
27	The incremental value of 18F-FDG PET/CT in paediatric malignancies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 630-637.	6.4	48
28	PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. <i>Journal of Nuclear Medicine</i> , 2007, 48, 234-9.	5.0	45
29	68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls. <i>Cancer Imaging</i> , 2018, 18, 39.	2.8	43
30	PET/CT imaging in infectious conditions. <i>Annals of the New York Academy of Sciences</i> , 2011, 1228, 150-166.	3.8	41
31	Pitfalls and Limitations of Radionuclide and Hybrid Imaging in Infection and Inflammation. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 500-512.	4.6	40
32	Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?. <i>Journal of Nuclear Medicine</i> , 2004, 45, 2045-51.	5.0	39
33	SPECT/CT in infection and inflammation. <i>Clinical and Translational Imaging</i> , 2014, 2, 519-535.	2.1	34
34	Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1129-36.	5.0	33
35	Metabolic PET/CT-Guided Lung Lesion Biopsies: Impact on Diagnostic Accuracy and Rate of Sampling Error. <i>Journal of Nuclear Medicine</i> , 2015, 56, 518-522.	5.0	32
36	Does Antibiotic Treatment Affect the Diagnostic Accuracy of ¹⁸ F-FDG PET/CT Studies in Patients with Suspected Infectious Processes?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1827-1830.	5.0	32

#	ARTICLE	IF	CITATIONS
37	PET/CT Imaging in Soft Tissue Infection and Inflammation—An Update. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 35-49.	4.6	30
38	Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2002, 94, 873-878.	4.1	29
39	Cardiovascular Infection and Inflammation. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 103-114.	4.6	28
40	Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1295-303.	5.0	28
41	Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. <i>Journal of Nuclear Medicine</i> , 2007, 48 Suppl 1, 28S-35S.	5.0	26
42	Whole-body bone SPECT in breast cancer patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 247-253.	1.1	25
43	Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. <i>Nuclear Medicine Communications</i> , 2016, 37, 1160-1168.	1.1	23
44	Preoperative [99mTc]MIBI SPECT/CT Interpretation Criteria for Localization of Parathyroid Adenomas—Correlation with Surgical Findings. <i>Molecular Imaging and Biology</i> , 2017, 19, 265-270.	2.6	19
45	DETECTION OF ISOLATED DISTANT METASTASIS IN SOFT TISSUE SARCOMA BY FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY: Case Report. <i>Pediatric Hematology and Oncology</i> , 2001, 18, 295-298.	0.8	15
46	Quantitative Analysis of Tight Junctions and the Uptake of 99mTc in Human Gliomas. <i>Cancer Investigation</i> , 1986, 4, 519-524.	1.3	11
47	The effect of CT-based attenuation correction on the automatic perfusion score of myocardial perfusion imaging using a dedicated cardiac solid-state CZT SPECT/CT. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 236-245.	2.1	10
48	Benign proliferative lesions mimicking recurrence of Hodgkin's disease. , 1997, 28, 187-190.		8
49	Strategies for Minimizing Occupational Radiation Exposure in Cardiac Imaging. <i>Current Cardiology Reports</i> , 2019, 21, 71.	2.9	7
50	Evaluation of Staff Radiation Exposure during Transthoracic Echocardiography Close to Myocardial Perfusion Imaging. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 763-770.	2.8	6
51	18F NaF PET/CT and Conventional Bone Scanning in Routine Clinical Practice. <i>PET Clinics</i> , 2012, 7, 315-328.	3.0	5
52	Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2002, 94, 873-8.	4.1	5
53	Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2106-2112.	6.4	5
54	The concentration of bleomycin labeled with Co-57 in primary and metastatic tumors. <i>Cancer</i> , 1989, 64, 988-993.	4.1	4

#	ARTICLE	IF	CITATIONS
55	Conduction abnormalities during dipyridamole stress testing. Journal of Nuclear Cardiology, 2017, 24, 405-409.	2.1	4
56	Clinical pretreatment risk factors and Ga ⁶⁷ scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer, 2002, 94, 873-878.	4.1	3
57	In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. Cancer, 1991, 67, 2477-2483.	4.1	2
58	Normal Distribution, Variants, Pitfalls, and Artifacts. , 2010, , 35-96.		1
59	The Global Reading Room: Nuclear Medicine Imaging of a Diabetic Foot Ulcer. American Journal of Roentgenology, 2022, , .	2.2	1
60	Preface. PET Clinics, 2006, 1, xi-xii.	3.0	0
61	Preface. PET Clinics, 2010, 5, ix.	3.0	0
62	Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.. Blood, 2006, 108, 4589-4589.	1.4	0